Skip to content
Baret News – Lifestyle
Author:
Protego Biopharma
Protego to Highlight PROT-001’s Potential to Target Light Chain Toxicity in AL Amyloidosis at ISA 2026
November 2, 2026
Protego Announces FDA IND Clearance for Phase 2/3 Study of PROT-001 in AL Amyloidosis
October 19, 2026
Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical Officer
June 8, 2026